Intrinsic Therapeutics Stock
Develops therapies to treat disc herniations in the spine for discectomy patients
About Intrinsic Therapeutics Stock
Intrinsic Therapeutics is a medical device company that develops therapies for treating disc herniations in the spine for discectomy patients. It offers Barricaid anular prosthesis that allows the direct reconstruction of weakened and ruptured annulus and soft tissues of the spine. The company also offers spinal implants to treat the causes of sciatica and low back pain. It serves surgeons and patients. The company was formerly known as Intrinsic Orthopedics and changed its name to Intrinsic Therapeutics in January 2003. Intrinsic Therapeutics was founded in 2000 and is based in Woburn, Massachusetts.
Funding History
| January 2001 | $7.2M |
|---|---|
| December 2002 | $25.0M |
| September 2007 | $21.0M |
| February 2010 | $18.0M |
| November 2012 | $11.6M |
| September 2014 | $17.3M |
| December 2016 | $17.9M |
| May 2017 | $28.0M |
| May 2017 | $21.0M |
| April 2019 | $52.0M |
Management
Vice President, Global Sales
Remco Maljers
CFO
David Neafus
Founder & Executive Director
Gregory Lambrecht
Vice President, Global Marketing
Ivo Scheepens
President and CEO
Cary Hagan
Chief Operating Officer
Jacob Einhorn
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Intrinsic Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
